Ophthalmology Therapeutics Market

Global Ophthalmology Therapeutics Market Size (2024 to 2032)

The global ophthalmology therapeutics market is forecasted to be worth USD 56.39 billion by 2032 from USD 31.85 billion in 2024. This market is projected to be growing at a CAGR of 7.4% during the forecast period.

Current Scenario of the Global Ophthalmology Therapeutics Market

Ophthalmology is a medicine and surgery branch that deals with diagnosing and treating eye disorders, using laser therapies and medications to perform surgeries. As per the World Health Organization, 2019, it is estimated that 2.2 billion people are visually impaired, over 39 million people have lost their vision, approximately 188.5 million have mild vision impairment, and above 217 million people have been experiencing moderate to severe vision impairment. In addition, vision eye care has become costly, with the consistent rise in the widespread ophthalmologic diseases worldwide, the increasing cost of treatment, and the rising need for ophthalmology.

MARKET DRIVERS

The global ophthalmology therapeutics market showcases evident potential in the mentioned forecasting period.

Ophthalmology is the branch of medicine associated with treating eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.The growing prevalence of ophthalmic diseases and the rising need for cost-effective ophthalmic disease therapeutics drive the growth of the ophthalmology therapeutics market.

An increase in presbyopia, molecular degeneration, and diabetic retinopathy is the market's primary driver. Furthermore, the ophthalmic disease market is expected to accelerate due to the increase in research & development activities and investment funding by the government and various private organizations to improve the healthcare infrastructure. In addition, the introduction of ophthalmic devices, advanced technologies, and people in emerging countries opting for ophthalmic surgeries to correct their eye-aligned problems are further expected to propel the market growth. 

The global market for ophthalmology therapeutics is further driven by the growing prevalence of vision impairment, estimated to be 147 million in 2010. It is estimated to reach 191 million in the world in 2020. Technological advancement in medicine also plays a significant role in the market's growth. Increasing the geriatric population worldwide and rising disposable income are other factors driving the global ophthalmology therapeutics market.

MARKET RESTRAINTS

Lack of awareness regarding the various diseases associated with ophthalmology is a major factor restraining the market's growth.

Stringent regulatory frameworks and unclear reimbursement policies are hurdles to market growth. Lack of awareness in rural areas about the various ophthalmic disorders and lack of health insurance covering all types of IOLs and contact lenses are restraining the market growth. Vision care has become costly; many people in all parts of the world cannot afford ophthalmic treatments. This is considered the primary factor for the declining global ophthalmology therapeutics market growth. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

Ophthalmology Therapeutics Market Analysis By Basis of Indication

Based on indication, the glaucoma segment is the most significant indication segment, accounting for approximately 31%, followed by AMD, with a share of 27%. Also, the retinal vein Occlusion segment held the largest market share in 2019. It dominated the market share owing to the increased prevalence of age-related molecular degeneration. Pipeline candidates working on VEGF inhibition principles will drive the segmentation growth during the forecast period.

Ophthalmology Therapeutics Market Analysis By End User

Based on the end-user, eye clinics and hospitals lead the market during the forecast period. The increasing prevalence of eye-related problems and the rising need for cost-effective ophthalmic disease therapeutics drive market growth.

REGIONAL ANALYSIS

Geographically, North America dominated the global ophthalmology therapeutics market in 2023, followed by Europe. Asia-Pacific is estimated to be the fastest-growing region during the forecast period. The domination of the North American market is attributed to the increasing awareness among the people about the benefits of ophthalmic drugs, and technological advancements have increased. Moreover, government measures and increased investments to improve the healthcare infrastructure propel market growth over the forecast period.

The European market held the second-largest share in the global ophthalmology therapeutics market in 2023. Increasing investments by the government and advancing healthcare infrastructure facilities are propelling the market. 

Asia Pacific is anticipated to grow at a healthy CAGR over the forecast period. The factors such as rising disposable income, improving economic scenario, and the large patient pool are fuelling the market demand. In addition, the increasing introduction of new product launches is boosting the market growth over these years. 

Middle East & Africa is expected to record a moderate share in the coming years. The increasing patient pool and rise in the prevalence of presbyopia are boosting the market growth in this region.

KEY PLAYERS IN THE OPHTHALMOLOGY THERAPEUTICS MARKET

Some of the most prominent companies leading the global ophthalmology therapeutics market profiled in the report are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

RECENT MARKET HAPPENINGS

• In December 2020, eye gate pharmaceuticals, including a clinical-stage company, focused on developing products to treat the eye.  

DETAILED SEGMENTATION OF THE GLOBAL OPHTHALMOLOGY THERAPEUTICS MARKET INCLUDED IN THIS REPORT

This research report on the global ophthalmology therapeutics market has been segmented and sub-segmented based on the indication, end-user, and region.

By Basis of Indication

• Glaucoma
• Dry Eye Syndrome
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration
• Macular Edema
• Allergic Conjunctivitis

By End User

• Hospitals
• Eye Clinics
• Diagnostic Centres
• Patients

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa